GENFIT S A/ADR (NASDAQ:GNFT) Sees Large Increase in Short Interest

GENFIT S A/ADR (NASDAQ:GNFT) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 13,800 shares, an increase of 42.3% from the August 31st total of 9,700 shares. Based on an average daily trading volume, of 32,600 shares, the short-interest ratio is presently 0.4 days.

Shares of NASDAQ:GNFT traded down $0.87 during mid-day trading on Thursday, reaching $4.40. The company had a trading volume of 225,225 shares, compared to its average volume of 82,474. The company has a current ratio of 6.66, a quick ratio of 6.66 and a debt-to-equity ratio of 2.13. The firm has a market cap of $199.38 million, a price-to-earnings ratio of -2.34 and a beta of 0.68. The company’s 50-day moving average price is $4.80 and its 200-day moving average price is $8.79. GENFIT S A/ADR has a one year low of $3.65 and a one year high of $22.48.

A hedge fund recently raised its stake in GENFIT S A/ADR stock. Morgan Stanley increased its stake in GENFIT S A/ADR (NASDAQ:GNFT) by 25.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,703 shares of the company’s stock after purchasing an additional 2,397 shares during the quarter. Morgan Stanley’s holdings in GENFIT S A/ADR were worth $173,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.04% of the company’s stock.

Several analysts have recently commented on GNFT shares. Stifel Nicolaus upgraded GENFIT S A/ADR from a “hold” rating to a “buy” rating in a research note on Thursday, July 23rd. Zacks Investment Research upgraded GENFIT S A/ADR from a “sell” rating to a “hold” rating in a research note on Tuesday, July 28th. HC Wainwright reiterated a “hold” rating and set a $8.00 price target on shares of GENFIT S A/ADR in a research note on Tuesday. Finally, Bank of America initiated coverage on GENFIT S A/ADR in a research note on Thursday, June 25th. They set an “underperform” rating and a $7.00 price target for the company. Four research analysts have rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. GENFIT S A/ADR has an average rating of “Hold” and an average target price of $41.00.


Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.

Featured Article: Why does the United States have a lingering trade deficit?

Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with's FREE daily email newsletter.